Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Antiemetic Prophylaxis with Granisetron and Fosaprepitant during Moderate and High Emetogenic Chemotherapy in Pediatric Patients

Michaela Döring, Dr. MD, Karin Melanie Cabanillas Stanchi, MSc, Manon Queudeville, Dr. MD, Ulrike Hartmann, Dr., Michael Ost, Dr. MD, Marie-Sarah Koch, Dr. MD, Carmen Malaval, Dr. MD, Markus Mezger, Dr. MD Dr. rer. nat., Sarah Schober, Dr. MD, Simone Weber, Dr. MD, Veit Lange, Dr. MD, Rupert Handgretinger, MD, Martin Ebinger, MD

Blood (2017) 130 (Supplement 1): 3228.

https://doi.org/10.1182/blood.V130.Suppl_1.3228.3228

Published: 2017

Journal Articles

Retrospective Analysis of Itraconacole, Voriconazole and Posaconazole As Oral Antifungal Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

Michaela Döring, MD, Olivia Blume, MS, Susanne Haufe, MS, Ulrike Hartmann, Pharmacologist, Astrid Kimmig, MD, Carl-Philipp Schwarze, MD, Rupert Handgretinger, MD, PhD, Ingo Müller, MD, PhD

Blood (2011) 118 (21): 3011.

https://doi.org/10.1182/blood.V118.21.3011.3011

Published: 2011

Journal Articles

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Stefan Balabanov, MD, PhD, Artur Gontarewicz, MD, Patrick Ziegler, PhD, Ulrike Hartmann, PhD, Mhairi Copland, MD, Ute Brassat, Ilona Hauber, PhD, Lothar Kanz, MD, Carsten Bokemeyer, MD, Alfred Nordheim, PhD, Joachim Hauber, PhD, Tessa L. Holyoake, MD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 1379.

https://doi.org/10.1182/blood.V108.11.1379.1379

Published: 2006

Journal Articles

Characterization of Bcr-Abl Positive Leukemic Cells under Long-Term In Vitro Treatment with Telomerase Inhibitor BIBR1532.

Ute Brassat, Stefan Balabanov, MD/PhD, Ulrike Hartmann, PhD, Daniel Rössler, Kerstin Borgmann, PhD, Judith Dierlamm, MD/PhD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 2185.

https://doi.org/10.1182/blood.V108.11.2185.2185

Published: 2006

Journal Articles

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Stefan Balabanov, Artur Gontarewicz, Patrick Ziegler, Ulrike Hartmann, Winfried Kammer, Mhairi Copland, Ute Brassat, Martin Priemer, Ilona Hauber, Thomas Wilhelm, Gerold Schwarz, Lothar Kanz, Carsten Bokemeyer, Joachim Hauber, Tessa L. Holyoake, Alfred Nordheim, Tim H. Brümmendorf

Blood (2006) 109 (4): 1701–1711.

https://doi.org/10.1182/blood-2005-03-037648

Published: 2006

Journal Articles

Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)–negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH

Fabian Beier, Stefan Balabanov, Tom Buckley, Klaus Dietz, Ulrike Hartmann, Markus Rojewski, Lothar Kanz, Hubert Schrezenmeier, Tim H. Brümmendorf

Blood (2005) 106 (2): 531–533.

https://doi.org/10.1182/blood-2004-10-3996

Published: 2005

Journal Articles

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Patrick Ziegler, PhD, Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer Kammer, PhD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD

Blood (2004) 104 (11): 2944.

https://doi.org/10.1182/blood.V104.11.2944.2944

Published: 2004

Journal Articles

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer, PhD, Patrick Ziegler, PhD, Martin Priemer, Gerold Schwarz, Lothar Kanz, MD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD

Blood (2004) 104 (11): 2957.

https://doi.org/10.1182/blood.V104.11.2957.2957

Published: 2004

Journal Articles

Imatinib mesylate affects the development and function of dendritic cells generated from CD34 + peripheral blood progenitor cells

Silke Appel, Andreas M. Boehmler, Frank Grünebach, Martin R. Müller, Anette Rupf, Markus M. Weck, Ulrike Hartmann, Volker L. Reichardt, Lothar Kanz, Tim H. Brümmendorf, Peter Brossart

Blood (2004) 103 (2): 538–544.

https://doi.org/10.1182/blood-2003-03-0975

Published: 2004

Journal Articles

Inhibitory effect of imatinib on normal progenitor cells in vitro

Kerol Bartolovic, Stefan Balabanov, Ulrike Hartmann, Martina Komor, Andreas M. Boehmler, Hans-Jörg Bühring, Robert Möhle, Dieter Hoelzer, Lothar Kanz, Wolf-Karsten Hofmann, Tim H. Brümmendorf

Blood (2004) 103 (2): 523–529.

https://doi.org/10.1182/blood-2003-05-1535

Published: 2004

Journal Articles

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

Tim H. Brümmendorf, Inci Ersöz, Ulrike Hartmann, Kerol Bartolovic, Stefan Balabanov, Alexandra Wahl, Peter Paschka, Sebastian Kreil, Tanja Lahaye, Ute Berger, Harald Gschaidmeier, Carsten Bokemeyer, Rüdiger Hehlmann, Klaus Dietz, Peter M. Lansdorp, Lothar Kanz, Andreas Hochhaus

Blood (2003) 101 (1): 375.

https://doi.org/10.1182/blood-2002-08-2557

Published: 2003

NARROW

Antiemetic Prophylaxis with Granisetron and Fosaprepitant during Moderate and High Emetogenic Chemotherapy in Pediatric Patients

Retrospective Analysis of Itraconacole, Voriconazole and Posaconazole As Oral Antifungal Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Characterization of Bcr-Abl Positive Leukemic Cells under Long-Term In Vitro Treatment with Telomerase Inhibitor BIBR1532.

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)–negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Imatinib mesylate affects the development and function of dendritic cells generated from CD34 + peripheral blood progenitor cells

Inhibitory effect of imatinib on normal progenitor cells in vitro

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only